Clinics in Dermatology
Volume 27, Issue 2 , Pages 202-209 , March 2009

Melatonin: circadian rhythm regulator, chronobiotic, antioxidant and beyond

References 

  1. Lezoual'h F, Skutella T, Widmann M, et al. Melatonin prevents oxidative stress-induced cell death in hippocampal cells. NeuroReport. 1996;7:2071–2077
  2. Borlongan CV, Yamamoto M, Takei N, et al. Glial cell survival is enhanced during melatonin-induced neuroprotection against cerebral ischemia. FASEB J. 1998;12:725–731
  3. Chen ST, Chuang JI. The antioxidant melatonin reduces cortical neuronal death after intrastriatal injection of kainate in the rat. Exp Brain Res. 1999;124:241–247
  4. Mayo JC, sainz RM, Uria H, et al. Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson's disease. J Pineal Res. 1998;24:179–192
  5. Hasegawa A, Ohtsubo K, Mori W. Pineal gland in old age; quantitative and qualitative morphological study of 168 human autopsy cases. Brain Res. 1987;409:343–349
  6. Swaab DF. In:  Aminoff MJ,  Francois B,  Swaab DF editor. The human hypothalamus basic and clinical aspects. Handbook of Clinical Neurology. vol 79:Amsterdam: Elsevier; 2003;p. 63–123
  7. Arendt J. In: Melatonin and the Mammalian Pineal Gland. London: Chapman & Hall; 1995;p. 27–59
  8. Dai J, Swaab DF, van der Vliet J, et al. Postmortem tracing reveals the organization of hypothalamic projections of the suprachiasmatic nucleus in the human brain. J Comp Neurol. 1998;400:87–102
  9. Reiter RJ. The melatonin rhythm: both a clock and a calendar. Experientia. 1993;49:654–664
  10. Coon SL, Del Olmo E, Young WS, et al. Melatonin synthesis enzymes in Mecaca mulatta: focus on arylalkylamine N-acetyltransferase (EC 2. 3. 1. 87). J Clin Endocrinol Metab. 2002;87:4699–4706
  11. Wu YH, Feenstra MG, Zhou JN, et al. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab. 2003;88:5898–5906
  12. Dai J, Van Der Vliet J, Swaab DF, et al. Humans retinohypothalamic tract as revealed by in vitro post-mortem tracing. J Comp Neurol. 1998;397:357–370
  13. Teclemariam-Mesbah R, Ter Horst GJ, Postema F, et al. Anatomical demonstration of the suprachiasmatic nucleus-pineal pathway. J Comp Neurol. 1999;406:171–182
  14. Skene DJ, Lockely SW, James K, et al. Correlation between urinary cortisol and 6-sulphatoxymeltonin rhythms in field studies of blind subjects. Clin Endocrinol. 1999;50:715–719
  15. Karasek M, Stankiewicz A, Bandurska-Stankiewicz E, et al. Melatonin concentrations in patients with large goiter before and after surgery. Neuroendocrinol Lett. 2000;21:437–439
  16. Bruce J, Tamarkin L, Riedel C, et al. Sequential cerebrospinal fluid and plasm sampling in humans: 24-hour melatonin measurements in normal subjects and after peripheral sympathectomy. J Clin Endocrinol Metab. 1991;72:819–823
  17. Oxenkrug GF, Anderson GF, Gragovic L, et al. Circadian rhythms of human pineal melatonin, related indoles, and beta adrenoreceptors: post-mortem evaluation. J Pineal Res. 1990;9:1–11
  18. Stoschitzky K, Sakotnik A, Lercher P, et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol. 1999;55:111–115
  19. Liu C, Weaver DR, Jin X, et al. Molecular dissection of two dinstinct actions of melatonin on the suprachiasmatic circadian clock. Neuron. 1997;19:91–102
  20. Fisher S, Smolnik R, Herms M, et al. Melatonin acutely improves the neuroendocrine architecture of sleep in blind individuals. J Clin Endocrinol Metab. 2003;88:5315–5320
  21. Spitzer RL, Terman M, Williamns JBW, et al. Jet lag: clinical features, validation of a new syndrome-specific scale, and lack of response to melatonin in a randomised, double-blind trial. Am J Psychiatry. 1999;156:1392–1396
  22. Herxhaimer A, Petrie KJ. In: Melatonin for the prevention and treatment of jet lag (Cochrane Review). Cochrane Library, Issue 3. Oxford: Update Software; 2001;p. 8
  23. Westchester IL. The international classification of sleep disorders: diagnostic and coding manual. Am Acad Sleep Med. 2005;
  24. Weitzman ED, Czeister CA, Coleman RM, Spielman AJ, Zimmerman JC, Dement W. Delayed sleep phase syndrome: a chronobiological disorder with sleep-onset insomnia. Arch Gen Psychiatry. 1981;38:137–146
  25. Kerkhof G, Vian Vianen B. Circadian phase estimation of chronic insomniacs relates to their sleep characteristics. Arch Physiol Biochem. 1999;107:383–392
  26. Watanabe T, Kajimura N, Kato M, et al. Sleep and circadian rhythm disturbances in patients with Delayed Sleep Phase Syndrome. Sleep. 2003;26:657–661
  27. Strogatz Sh, Kronauer RE. Circadian wake maintenance zones and insomnia in man. Sleep Res. 1985;14:219
  28. Dawson D, Lack L, Morris M. Phase resetting of the human circadian pacemaker with use of a single pulse of bright light. Chronobiol Int. 1999;10:94–102
  29. Sack R, Lewy A, Hughes R. Use of melatonin for sleep and circadian rhythm disorders. Ann Med. 1998;30:115–121
  30. Lewy A, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to phase-response curve. Chronobiol Int. 1992;9:380–392
  31. Revell VL, Burgess HJ, Gazda CJ, Smith MR, Fogg LF, Eastman CI. Advancing human circadian rhythms with afternoon melatonin and morning intermittent bright light. J Clin Endocrinol Metab. 2006;91:54–59
  32. Buscemi N, Vandermeer B, Hooton N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders: A meta-analysis. J Gen Intern Med. 2005;20:1151–1158
  33. Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev. 2005;9:41–50
  34. Hardeland R, Poeggeler B. Non-vertebrate melatonin. J Pineal Res. 2003;34:233–234
  35. Srinivasan V, Pandi-Perumal SR, Cardinali DP, Poeggler B, Harderland R. Melatonin in Alzheimer's disease and other neurodegenerative disorders. Behav Brain Funct. 2006;2–15
  36. Tan DX, Reiter RJ, Manchester LC, et al. Chemical and physical properties and potential mechanism: melatonin as a broad spectrum antioxidant and free rdical scavenger. Curr Top Med Chem. 2002;2:181–197
  37. Buyukavci M, Ozdemir O, Buck S, Stout M, Ravindranath Y, Savasan S. Melatonin cytotoxicity in human leukaemia cells: relation with its prooxidant effect. Fundam Clin Pharmacol. 2006;20:73–79
  38. Lahiri DK, Ge YW, Sharman EH, Bondy SC. Age-related changes in serum melatonin in mice: higher levels of combined melatonin and 6-hydroxymelatonin sulphate in the cerebral cortex than serum, heart, liver and kidney tissues. J Pineal Res. 2004;36:217–223
  39. Sanchez-Moreno C, Dorfman SE, Lichtenstein AH, Martin A. Dietary fat type affects vitamins C and E and biomarkers of oxidative status in peripheral and brain tissue of golden Syrian hamsters. J Nutr. 2004;134:655–660
  40. Filadelfi AM, Castrucci AM. Comparative aspects of the pineal melatonin system of poikilothermic vertebrates. J Pineal Res. 1996;20:175–186
  41. Kotler M, Rodriguez C, Sainz RM, Antolin I, Menendez-Pelaez A. Melatonin increases gene expression for antioxidant enzymes in rat brain cortex. J Pineal Res. 1998;24:83–89
  42. Rodriguez C, Mayo JC, Sainz RM, Antolin I, Herrera F, Martin V, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004;36:1–9
  43. Anisimov SV, Popovic N. Genetic aspects of melatonin biology. Rev Neurosci. 2004;15:209–230
  44. Reiter RJ, Acuna-Castroviejo D, Tan DX, Burkhardt S. Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann N Y Acad Sci. 2001;939:200–215
  45. Conway S, Drew JE, Mowat P, Barret P, Delagrange P, Morgan PJ. Chimeric melatonin mtl and melatonin-related receptors. Identification of domains and residues participating in ligand binding and receptor activation of the melatonin mtl receptor. J Biol Chem. 2000;275:20602–20609
  46. Garcia-Maurino S, Pozo D, Calvo JR, Guerrero JM. Correlation between nuclear melatonin receptor expression and enhanced cytokine production in human lymphocytic and monocytic cell lines. J Pineal Res. 2000;29:129–137
  47. Carlberg C, Wiesenberg I. The orphan receptor family RZR/ROR, melatonin and 5-lipoxygenase. An unexpected relationship. J Pineal Res. 1995;18:171–178
  48. Yu BP, Chung HV. Adaptive mechanism to oxidative stress during aging. Mech Ageing Dev. 2006;127:436–443
  49. Skene DJ, Swaab DF. Melatonin rhythmicity: effect of age and Alzheimer's disease. Exp Gerontol. 2003;38:199–206
  50. Duffy JF, Zeitzer JM, Rimmer DW, et al. Peak of circadian melatonin rhythm occurs later within the sleep of older subjects. Am J Physiol Endocrinol Metab. 2002;282:E297–E303
  51. Kunz D, Schmitz S, Mahlberg R, et al. A new concept for melatonin deficit: on pineal calcification and melatonin excretion. Neuropsychopharmacology. 1999;21:765–772
  52. Kunz D, Bes F, Schlattmann P, et al. On pineal calcification and its relation to subjective sleep perception: a hypothesis-driven pilot study. Psychiatry Res. 1998;82:187–191
  53. Urata Y, Honma S, Goto S, et al. Melatonin induces glutamylcysteine synthase mediated by activator protein-I in human vascular endothelial cells. Free Radic Biol Med. 1999;27:838–847
  54. Martin M, Macias G, Escames G, et al. Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo. J Pineal Res. 2000;28:242–248
  55. Harrison T, Churcher I, Beher D. Gamma-secretase as a target for drug intervention in Alzheimer's disease. Curr Opin Drug Discov Devel. 2004;7:709–719
  56. Zatta P, Tognon G, Carampin P. Melatonin prevents free radical formation due to the interaction between beta-amyloid peptides and metal ions [Al(III), Zn(II), Cu(II), Mn(II), Fe(II)]. J Pineal Res. 2003;35:98–103
  57. Acuna-Castroviejo D, Martin M, Macias M, et al. Melatonin, mitochondria, and cellular bioenergetics. J Pineal Res. 2001;30:65–74
  58. Liu RY, Zhou JN, Van Heerikhuize J, Hofman MA, Swaab DF. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab. 1999;84:323–327
  59. Beal MF. Mitochondria, free radicals, and neurodegeneration. Curr Opin Neurobiol. 1996;6:661–666
  60. Floyd RA, Hensley K. Oxidative stress in brain aging, Implications fot therapeutics of neurodegenerative diseases. Neurobiol Aging. 2002;23:795–807
  61. Huang X, Moir RD, Tanzi RE, Bush AI, Rogers JT. Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann N Y Acad Sci. 2004;1012:153–163
  62. Zhu X, Raina AK, Perry G, Smith MA. Alzheimer's disease:the two-hit hypothesis. Lancet Neurol. 2004;3:219–226
  63. Cheng Y, Feng Z, Zhang QZ, Zhang JT. Beneficial effects of melatonin in experimental models of Alzheimer disease. Acta Pharmacol Sin. 2006;2:129–139
  64. Blennow K, Cowburn RF. The neurochemistry of Alzheimer's disease. Acta Neurol Scand. 1996;168(Suppl):77–86
  65. Ancoli -Israel S, Klauber MR, Jones DW, et al. Variations in circadian rhythms of activity, sleep, and light exposure related to dementia in nursing-home patients. Sleep. 1997;20:18–23
  66. Martin J, Marler M, Shochat T, et al. Circadian rhythms of agitation in institutionalized patients with Alzheimer's disease. Chronobiol Int. 2000;17:405–418
  67. Ohashi Y, Okamoto N, Uchida K, et al. Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer's type. Biol Psychiatry. 1999;45:1646–1652
  68. Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer's disease. J Pineal Res. 2005;38:145–152
  69. Zhou JN, Liu RY, Kamphorst W, et al. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res. 2003;35:125–130
  70. Pappola MA, Chyan YJ, Poeggeler B, et al. An assessment of the antioxidant and antiamyloidogenic properties of melatonin: Implications for Alzheimer's disease. J Neural Transm. 2000;107:203–231
  71. Rousseau A, Petren S, Plannthin J, et al. Serum and cerebrospinal fluid concentrations of melatonin: a pilot study in healthy male volunteers. J Neural Transm. 1999;106:883–888
  72. Reiter RJ, Tan DX, Machester LC, et al. Melatonin reduces oxidant damage and promotes mitochondrial respiration: implications for aging. Ann N Y Acad Sci. 2002;959:238–250
  73. Pardo CA, Martin LJ, Troncoso JC, et al. The human pineal gland in aging and Alzheimer's disease: patterns of cytoskeletal antigen immunoreactivity. Acta Neuropathol. 1990;80:535–540
  74. Liu RY, Zhou JN, Hoogenduk WJ, et al. Decreased vasopressing gene expression in the biological clock of Alzheimer disease patients with and without depression. J Neuropathol Exp Neurol. 2000;59:314–322
  75. Van De Nes JA, Kamphorst W, Ravid R, et al. Comparison of beta-protein/A4 deposits and Alz-50-stained cytoskeletal changes in the hypothalamus and adjoining areas of Alzheimer's disease patients: amorphic plaques and cytoskeletal changes occur independently. Acta Neuropathol. 1998;96:129–138
  76. Stopa EG, Volicer L, Kuo-Leblanc V, et al. Pathologic evaluation of the human suprachiasmatic nucleus in severe dementia. J Neuropathol Exp Neurol. 1999;58:29–39
  77. Campbell SS, Kripke DF, Gillin JC, et al. Exposure to light in healthy elderly subjects and Alzheimer's patients. Physiol Behav. 1998;42:141–144
  78. Blanks JC, Torigoe Y, Hinton DR, et al. Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging. 1996;17:377–384
  79. Blanks JC, Schmidt SY, Torigoe T, et al. Retinal pathology in Alzheimer's disease. II. Regional neuron loss and glial changes in GCL. Neurobiol Aging. 1996;17:385–395
  80. Cohen-Mansfield J, Garfinkel D, Lipson S. Melatonin for treatment of sundowning in elderly persons with dementia – a preliminary study. Arch Gerontol Geriatr. 2000;31:65–76
  81. Brusco LI, Marquez M, Cardinali DP. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuroendocrinol. Letter. 2000;21:39–42
  82. Cardinali DP, Brusco LI, Liberczuk C, et al. REVIEW. The use of melatonin in Alzheimer's disease. Neuroendocrinol Lett. 2002;23:20–23
  83. Singer C, Tractenberg RE, Kaye J, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep. 2003;26:893–901
  84. Sefarty M, Kennel-Webb S, Warner J, et al. Double blind rendomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int J Geriatr Psychiatry. 2002;17:1120–1127

PII: S0738-081X(08)00072-2

doi: 10.1016/j.clindermatol.2008.04.003

Clinics in Dermatology
Volume 27, Issue 2 , Pages 202-209 , March 2009

Article Tools